CAMBRIDGE, Mass.--(BUSINESS WIRE)--Satellite Bio emerged from stealth today to reveal first-in-kind Tissue Therapeutics, bioengineered tissues that repair, restore or replace critical organ or tissue ...

Satellite Biosciences, Inc. (Satellite Bio), a clinical-stage biotechnology company developing off-the-shelf liver therapies ...

For years, researchers have striven to repair, restore, even replace diseased tissue or organs through therapies based on regenerated cells. Such therapies pose challenges ranging from manufacturing, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Science that was fine-tuned in the labs of MIT and Boston ...

Satellite Biosciences Inc. has become the latest biotech to emerge from stealth, backed with more than $110 million in VC financing to develop bioengineered tissues that fix damaged tissues or organs.

The US FDA has granted Rare Paediatric Disease (RPD) designation for Satellite Bio’s SB-101 for the treatment of urea cycle disorders (UCDs)., Satellite Bio is a biotechnology company developing ...

Satellite Bio, a Cambridge startup focused on developing tissue implants to “repair, restore, or even replace” diseased or dying organs, launched Wednesday with $110 million in funding. The company, ...